Chester County News and Community Website
KING OF PRUSSIA, PA — CSL (ASX: CSL; USOTC: CSLLY) has unveiled four-year results from its pivotal HOPE-B study, demonstrating the long-term durability and safety of HEMGENIX® (etranacogene dezaparvovec-drlb), the …
CSL Reports Promising Four-Year Data on Gene Therapy for Hemophilia B Read More
MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN) has reached a significant milestone in the development of its gene-agnostic therapy, OCU400, as the European Commission has delivered a positive opinion designating it …
Ocugen’s OCU400 Receives ATMP Classification from European Commission, Advancing Retinitis Pigmentosa Treatment Read More MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN) has announced a positive 2-year safety and efficacy update from its Phase 1/2 clinical trial for OCU400, a groundbreaking gene therapy targeting retinitis pigmentosa …
Breakthrough in Vision: Ocugen’s OCU400 Shows Promising 2-Year Results for Retinitis Pigmentosa Read More
PHILADELPHIA, PA — Interius BioTherapeutics has secured approval from Germany’s Paul Ehrlich Institute (PEI) to expand its pioneering INVISE Phase 1 clinical trial into Europe. This marks the first-ever clearance …
Interius BioTherapeutics Expands Groundbreaking Gene Therapy Trial to Europe Read More
WASHINGTON, D.C. — The U.S. Food and Drug Administration (FDA) has announced a groundbreaking approval of Kebilidi (eladocagene exuparvovec-tneq), marking the first gene therapy sanctioned for the treatment of aromatic L-amino …
Revolutionary Gene Therapy Approved: Kebilidi Offers New Hope for Rare Genetic Disorder Read More
BERWYN, PA — AscellaHealth has reaffirmed its commitment to Gene Therapy and Specialty Pharmacy Awareness Month for the third year, as recognized by the Society for Health Care Strategy & Market …
AscellaHealth Champions Gene Therapy and Specialty Pharmacy Awareness Month Read More MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN) has reached a significant milestone in its GARDian clinical trial for OCU410ST, a promising gene therapy aimed at treating Stargardt disease. The company …
Ocugen Advances Gene Therapy Trial for Stargardt Disease Read More MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN) has received approval from Health Canada to begin the Phase 3 liMeliGhT clinical trial for their OCU400 gene therapy. This trial aims to …
Ocugen Expands Gene Therapy Trial to Canada Read More
CONSHOHOCKEN, PA — Alcura, a part of Cencora, has received a Manufacturing and Importation Authorization (MIA) license for cell and gene therapies (CGT) from the Spanish Agency of Medicines and …
Alcura Secures MIA License to Enhance Cell and Gene Therapy Importation Read More MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN) has received approval from the Food and Drug Administration to begin its expanded access program (EAP) for the treatment of adult patients with …
Ocugen Receives FDA Approval for Expanded Access Program for Retinitis Pigmentosa Treatment Read More